Simvastatin, a competitive inhibitor of HMG‐CoA reductase, lowers cholesterol saturation index of gallbladder bile

113Citations
Citations of this article
16Readers
Mendeley users who have this article in their library.

Abstract

We tested the possibility that simvastatin, a competitive inhibitor of HMG‐CoA reductase related to mevinolin, might alter cholesterol saturation of gallbladder bile. Ten patients with Type IIa or IIb hypercholesterolemia underwent bile sampling before, and again after, treatment with 20 or 40 mg per day simvastatin for 7 to 13 weeks. Mean cholesterol saturation index of gallbladder bile fell from 1.01 to 0.77 during simvastatin treatment (p < 0.01). This finding strongly suggests that treatment with HMG‐CoA reductase inhibitors will not predispose to development of cholesterol gallstones. Indeed, it raises the possibility that such inhibitors might have a future role to play in treatment of gallstones. Copyright © 1988 American Association for the Study of Liver Diseases

Cite

CITATION STYLE

APA

Duane, W. C., Hunninghake, D. B., Freeman, M. L., Pooler, P. A., Schlasner, L. A., & Gebhard, R. L. (1988). Simvastatin, a competitive inhibitor of HMG‐CoA reductase, lowers cholesterol saturation index of gallbladder bile. Hepatology, 8(5), 1147–1150. https://doi.org/10.1002/hep.1840080531

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free